$AVNR News U.S. stock futures cut rise after retail sales

New Post Public Reply Private Reply Replies (0) Message Board

Dec 16, 2013 at 2:06 PM

$AVNR News

U.S. stock futures cut rise after retail sales 7:53 a.m. Aug. 13, 2013 - Barbara Kollmeyer
Cree, Flowers Foods in focus Tuesday 7:42 a.m. Aug. 13, 2013 - Wallace Witkowski
Yum Brands shares drop on sour China sales 4:23 p.m. Aug. 12, 2013 - Wallace Witkowski
Avanir to promote Merck's diabetes drug Januvia 3:48 p.m. Aug. 12, 2013 - MarketWatch.com
Avanir shares rise after hours on license deal 5:29 p.m. July 2, 2013 - Wallace Witkowski
Avanir, OptiNose enter N. America licensing deal 4:27 p.m. July 2, 2013 - MarketWatch.com
7 gut checks before the stock market's opening bell 5:43 a.m. April 29, 2013 - Shawn Langlois
Avanir Pharmaceuticals shares down 3% 9:37 a.m. Nov. 17, 2010 - Nick Godt
Monday’s biggest gaining and declining stocks 4:25 p.m. Nov. 1, 2010 - Laura Mandaro
Avanir and Allergan lead drug stocks 12:55 p.m. Nov. 1, 2010 - Val Brickates Kennedy
Avanir leads drug stocks north 9:06 a.m. Nov. 1, 2010 - Val Brickates Kennedy
Rexahn, Avanir gain; Sequenom falls 12:32 p.m. April 7, 2010 - Val Brickates Kennedy
Avanir, Opexa gain ahead of presentations 2:16 p.m. April 6, 2010 - Val Brickates Kennedy
Avanir shares jump 10% in pre-market action 8:27 a.m. April 6, 2010 - Val Brickates Kennedy
Drug stocks pressured by J&J report; Avanir jumps 12:49 p.m. Oct. 13, 2009 - Val Brickates Kennedy
Avanir, Acorda move on MS drug updates 2:51 p.m. Oct. 9, 2009 - Val Brickates Kennedy
Tuesday's biggest gaining and declining stocks 5:10 p.m. Aug. 11, 2009 - MarketWatch
Avanir soars and Javelin sinks on drug studies 12:15 p.m. Aug. 11, 2009 - Val Brickates Kennedy
Avanir Pharmaceuticals shares up 85% 8:41 a.m. Aug. 11, 2009 - Nick Godt
Avanir climbs on Phase III Zenvia trial success 6:31 a.m. Aug. 11, 2009 - Steve Goldstein

Mid-Afternoon Market Update: Markets Falling as Smith & Wesson Continues to Rise on Earnings 3:02 p.m. Dec. 11, 2013 - benzinga.com
Mid-Day Market Update: Smith & Wesson Gains On Upbeat Profit; LabCorp Shares Decline 11:29 a.m. Dec. 11, 2013 - benzinga.com
Summer Street defends Avanir after trial miss 10:38 a.m. Dec. 11, 2013 - Seeking Alpha
Mid-Morning Market Update: Markets Fall; Joy Global Profit Misses Estimates 10:37 a.m. Dec. 11, 2013 - benzinga.com
Avanir Reports Wider Loss - Analyst Blog 10:37 a.m. Dec. 11, 2013 - Zacks.com
Zacks #5 Rank Additions for Wednesday - Tale of the Tape 9:30 a.m. Dec. 11, 2013 - Zacks.com
Morning Market Losers 9:05 a.m. Dec. 11, 2013 - benzinga.com
Benzinga's Top #PreMarket Losers 7:34 a.m. Dec. 11, 2013 - benzinga.com
Benzinga's Top Downgrades 7:13 a.m. Dec. 11, 2013 - benzinga.com
Wednesday’s Biggest Stock Losers – AVNR, OPK and More 6:19 a.m. Dec. 11, 2013 - InvestorPlace.com
10-K: AVANIR PHARMACEUTICALS, INC. 6:09 a.m. Dec. 11, 2013 - Edgar Online - (EDG = 10Q, 10K)
Avanir's CEO Discusses F4Q 2013 Results - Earnings Call Transcript 8:08 p.m. Dec. 10, 2013 - Seeking Alpha
Avanir -13.8% AH, AVP-923 misses primary efficacy endpoint in phase II trial 5:36 p.m. Dec. 10, 2013 - Seeking Alpha
Q4 2013 AVANIR PHARMACEUTICALS Earnings Conference call (Webcast) 4:25 p.m. Dec. 10, 2013 - Seeking Alpha
Earnings Scheduled For December 10, 2013 4:14 a.m. Dec. 10, 2013 - benzinga.com
An Analysis Into Avanir Pharmaceuticals Neutralizes Concern And Reveals Potential 10:44 a.m. Dec. 9, 2013 - Seeking Alpha
Avanir Pharmaceuticals' CEO Presents at 25th Annual Piper Jaffray Health Care Conference (Transcript) 12:26 p.m. Dec. 4, 2013 - Seeking Alpha
Avanir Pharmaceuticals' Management Presents at Deutsche Bank BioFEST Conference (Transcript) 11:43 a.m. Dec. 3, 2013 - Seeking Alpha
AVNR January 2015 Options Begin Trading 10:59 a.m. Nov. 8, 2013 - TheStreet.com
Insider Trading Alert - AVNR, ALK, BIIB, VRX And RAI Traded By Insiders 11:15 a.m. Nov. 6, 2013 - TheStreet.com

Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health 8:00 a.m. Today - PR Newswire
Technical Research on Equities: Zoetis, Actavis, Avanir Pharma, and Salix Pharma 8:00 a.m. Today - PR Newswire
Important Stocks Scan List: Nokia Corporation, BlackBerry Ltd, Sprint Corporation, Avanir Pharmaceuticals 9:03 a.m. Dec. 11, 2013 - ACCESSWIRE
Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results 4:00 p.m. Dec. 10, 2013 - PR Newswire
Avanir Pharmaceuticals Announces Results for Phase II PRIME Study 4:00 p.m. Dec. 10, 2013 - PR Newswire
Avanir Pharmaceuticals Announces Date of Fiscal 2013 Fourth Quarter Financial Results and Conference Call 8:00 a.m. Dec. 3, 2013 - GlobeNewswire
Avanir Pharmaceuticals to Participate in Two Conferences in December 8:30 a.m. Nov. 26, 2013 - PR Newswire
Stock Price Update, Recognitions, and Grant of Stock Options - Research Report on Cyberonics, Hill-Rom Holdings, Bio-Reference Laboratories, Avanir Pharmaceuticals, and ImmunoGen 8:00 a.m. Nov. 21, 2013 - PR Newswire
Before the Bell Scans: Zoetis Inc., Avanir Pharma, Actavis PLC, and Salix Pharmaceuticals Ltd 8:01 a.m. Nov. 13, 2013 - PR Newswire
Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares 8:00 a.m. Nov. 11, 2013 - PR Newswire
Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 4:00 p.m. Nov. 8, 2013 - PR Newswire
Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information 7:30 a.m. Oct. 29, 2013 - PR Newswire
Recognitions, Patent Issuance, Financial Results, Upcoming Investor Conferences and Update on ClinicalTrial - Research Report on Stereotaxis, Immunomedics, Novadaq, Avanir, and Raptor Pharmaceuticals 8:00 a.m. Oct. 28, 2013 - PR Newswire
Technical Study: Zoetis Inc., AVANIR Pharma Inc., Actavis plc, and Salix Pharma Ltd 8:18 a.m. Oct. 24, 2013 - PR Newswire
Avanir Pharmaceuticals to Host Investor Day on October 29, 2013 7:30 a.m. Oct. 23, 2013 - PR Newswire
Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease 7:30 a.m. Oct. 22, 2013 - PR Newswire
Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 3:15 p.m. Oct. 4, 2013 - PR Newswire
Today's Technical View: Avanir Pharmaceuticals Inc., Warner Chilcott PLC, Actavis Inc., and Dynavax Technologies Corp. 10:48 a.m. Oct. 1, 2013 - PR Newswire
Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache" 7:30 a.m. Sept. 20, 2013 - PR Newswire
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Avanir Pharmaceuticals, Inc. 7:30 a.m. Sept. 16, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...